Table 1

Demographic features of patients and controls

RA-TNF1 (n = 38)

RA-TNF2 (n = 38)

TNF-naive RA

(n = 40)

TB

(n = 30)

Leprosy

(n = 23)

Healthy controls

(n = 41)


F:M

31:7

31:7

29:11

21:9

7:16

29:12


Mean age (years)

51.7 ± 14.2

51.7 ± 14.2

52.6 ± 13.5

43.0 ± 13.4

57.1 ± 9.6

41.1 ± 12.1


BCG scar (+)

24

24

25

23

16

27


QTF


(+)

13 (34%)

16 (42%)

20 (50%)

15 (50%)

14 (61%)

19 (47%)


(-)

23 (61%)

22 (58%)

19 (47%)

13 (43%)

8 (35%)

22 (53%)


Indeterminate

2 (5%)

0

1 (3%)

2 (7%)

1 (4%)

0


TST


10 mm (+)

9 (24%)

14 (37%)

22 (55%)

17 (57%)

13 (57%)

28 (68%)


5 mm (+)

10 (26%)

17 (45%)

24 (60%)

21 (70%)

14 (61%)

33 (80%)


Results in rheumatoid arthritis patients before (RA-TNF1) and after (RA-TNF2) treatment with TNF-α antagonists, rheumatoid arthritis patients who were not prescribed TNF-α antagonists (TNF-naive RA), rheumatology patients who had current or past confirmed tuberculosis infection (TB), leprosy patients, and healthy controls.

Hatemi et al. Arthritis Research & Therapy 2012 14:R147   doi:10.1186/ar3882

Open Data